Virtual ACC 2020 | ISCHEMIA-CKD: Invasive Strategy vs. Medical Treatment in Higher Risk Patients

This pre-specified protocol originally included 777 patients with chronic kidney failure. These patients are a special population of higher risk where we might be able to see the advantage of a more aggressive initial strategy. Death or MI rate (combined primary end point) resulted 36.4% for the invasive strategy vs. 36.7% for the initially conservative<a href="https://solaci.org/en/2020/04/03/virtual-acc-2020-ischemia-ckd-invasive-strategy-vs-medical-treatment-in-higher-risk-patients/" title="Read more" >...</a>

ACC 2020 Virtual | El controvertido estudio ISCHEMIA llega finalmente a NEJM

Virtual ACC 2020 | Controversial Trial ISCHEMIA Finally in NEJM

In November 2019, during the American Heart Association (AHA) 2019 Scientific Sessions, researchers presented this revolutionary trial that called the attention of all cardiologists. We had to wait until March to read the fine print; back then, a global pandemic such as the current one seemed out of a science-fiction tale. The world has changed<a href="https://solaci.org/en/2020/04/01/virtual-acc-2020-controversial-trial-ischemia-finally-in-nejm/" title="Read more" >...</a>

mas-leido-febrero-eng-420x283-compressor

The Most Read Scientific Articles of February

01- Alternatives for Patients Allergic to Aspirin The new guidelines of chronic coronary syndromes make class IIb recommendations to use prasugrel or ticagrelor in aspirin-intolerant patients. This is not meant to replace dual antiaggregation therapy in aspirin intolerant patients, when needed; it is just a recommendation to use monotherapy with the most potent antiaggregant we<a href="https://solaci.org/en/2020/03/11/the-most-read-scientific-articles-of-february/" title="Read more" >...</a>

TCT 2019 | EURO-CTO: Results at 3 Years of CTO Recanalization vs. Optimal Medical Treatment

Courtesy of SBHCI. Between 16 and 18% of coronary artery lesions in patients with chronic stable CAD are chronic total occlusions (CTO). CTO revascularization could benefit symptomatic patients, but it remains unclear whether such complex procedure is safe in the long run, given the study outcomes on PCI in CAD so far. This study presented<a href="https://solaci.org/en/2019/10/01/tct-2019-euro-cto-results-at-3-years-of-cto-recanalization-vs-optimal-medical-treatment/" title="Read more" >...</a>

EuroPCR 2019 | BASKET-SMALL 2: balones farmacológicos vs DES en vasos pequeños

EuroPCR 2019 | BASKET-SMALL 2: Drug-Coated Balloons vs. DES in Small Vessels

This angiographic substudy supports the safety of drug-coated balloons in small vessels. Despite better angiographic outcomes, there were eight cases of stent thrombosis among drug-eluting stent (DES) patients, while there was none with drug-coated balloons. In patients with small vessels, using a drug-coated balloon appears safe and comparable to DES, with favorable angiographic outcomes at<a href="https://solaci.org/en/2019/05/27/europcr-2019-basket-small-2-drug-coated-balloons-vs-des-in-small-vessels/" title="Read more" >...</a>

EuroPCR 2019 | Global Leaders: La monoterapia con ticagrelor a largo plazo podría tener un lugar en angioplastias complejas.

EuroPCR 2019 | Global Leaders: Ticagrelor Monotherapy at Long Term Could Have a Role in Complex PCI

This post hoc analysis of what had been a trial with negative outcomes should be considered only as a hypothesis generator. Patients receiving complex PCI treated with ticagrelor monotherapy after one-month dual antiaggregation therapy (DAPT) showed better results at 2 years when compared against patients receiving a conventional DAPT scheme. In the global analysis, this<a href="https://solaci.org/en/2019/05/23/europcr-2019-global-leaders-ticagrelor-monotherapy-at-long-term-could-have-a-role-in-complex-pci/" title="Read more" >...</a>

Clinical Utility of CT-Derived FFR for Decision-Making

In this large international multicenter population, computed-tomography (CT)-derived fractional flow reserve (FFR) modified treatment recommendation in two-thirds of subjects compared with CT angiography alone, and it was associated with less negative invasive angiographies. It also predicted revascularization and identified low-risk patients. A non-invasive means to know the anatomy and function of patients with stable chronic<a href="https://solaci.org/en/2018/11/21/clinical-utility-of-ct-derived-ffr-for-decision-making/" title="Read more" >...</a>

Los 10 artículos más leídos de septiembre

The 10 most read articles of September

1- High-Sensitivity Troponins Turned All Events into Infarctions; the 4th Universal Definition Clarifies Things Myocardial infarction or myocardial injury? The Fourth Universal Definition of Myocardial Infarction (an update of the 2012 version) is here to clarify that not all cases of elevated cardiac troponin values are acute myocardial infarctions. Read more   2- A Simple<a href="https://solaci.org/en/2018/10/09/the-10-most-read-articles-of-september/" title="Read more" >...</a>

8 artículos sobre Oclusiones Crónicas Totales que no puede dejar de leer

An Effort Worth Your While: Rechanneling vs. Optimal Medical Treatment in Total Occlusions

Successful rechanneling of a chronic total occlusion (currently around 90%) leads to significant improvement in quality of life and symptom frequency in patients with stable chronic angina compared with optimal medical treatment alone. These results are promising and what we ultimately expected, although symptoms, as a primary endpoint in themselves, are in the eye of<a href="https://solaci.org/en/2018/09/14/an-effort-worth-your-while-rechanneling-vs-optimal-medical-treatment-in-total-occlusions/" title="Read more" >...</a>

CLARIFY: No hay beneficio en sobrevida con betabloqueantes más allá de un año post infarto

ESC 2018 | CLARIFY: No Survival Benefit with Beta-Blockers Beyond 1 Year After Infarction

This is another study that concludes that beta-blockers have no impact on mortality at 1 year after infarction in stable patients and offer no survival benefit to patients with stable ischemic heart disease who have not experienced a myocardial infarction. This analysis represents 5 years of follow-up in a large, multinational registry and also shows a lack<a href="https://solaci.org/en/2018/08/29/esc-2018-clarify-no-survival-benefit-with-beta-blockers-beyond-1-year-after-infarction/" title="Read more" >...</a>

chronic stable angina